

Medgate extends licence agreement and plans to expand use

- **Medgate is a leading provider of digital health and telemedicine services and operates Europe's largest telemedical centre run by doctors**
- **Extension follows an initial one-year licence agreement (refer ASX announcement 4 August 2021)**
- **Medgate to extend use of ResAppDx to further patient journeys and expand to Germany**

Brisbane, Australia, 7 July 2022 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that it has agreed to a 12 month extension to its commercial licence agreement with Medgate AG ("Medgate") to use ResApp's smartphone-based acute respiratory diagnostic test, ResAppDx, on Medgate's telehealth platform (refer ASX announcement 4 August 2021).

Medgate is a leading provider of telehealth services and since 2000 has operated the largest telemedical centre run by doctors in Europe. The group employs over 510 people worldwide, including over 200 physicians.

ResApp's acute respiratory diagnostic test, ResAppDx, uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone's inbuilt microphone. ResAppDx is CE Marked in Europe and TGA approved for ARTG (Australian Register of Therapeutic Goods) listing in Australia.

Medgate plans to also expand the use of ResAppDx across additional patient journeys in its telemedicine services and will expand use into Germany in 2023.

ResApp's CEO and Managing Director, Dr Tony Keating said: *"Medgate is a long-standing, global leader in telehealth and we are proud to extend our commercial licence agreement. It's pleasing to see that Medgate extending the use of ResAppDx to additional patient journeys for the benefit of more patients and clinicians. We believe this is further strong endorsement of the value of ResAppDx to patients, clinicians and telehealth providers."*

Dr Andy Fischer, CEO Medgate added: *"ResApp continues to be an exemplary partner and over the course of the last 12 months we've built further evidence of the benefits of ResAppDx to our clinicians and patients. We look forward to expanding our use of ResAppDx to further realise these benefits for our patients. Our intention is to be the most innovative leader in the global telehealth market and the adoption of ResApp's AI plays an important role in helping us to achieve this by transforming the patient journey."*

###



About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

About Medgate AG

Medgate brings the physician to where he or she is needed by patients and relies on Digital Health solutions to do so. The focus is on the well-being of the patient and the benefits to society. Medgate was founded in Switzerland in 1999 and today employs over 510 people worldwide. Since 2000, Medgate has been operating the largest medical telemedicine center in Europe and thus has an extraordinary amount of experience and knowledge in telemedicine. Medgate is also present in Germany and the Philippines. www.medgate.care

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.